MicroRNA-145 suppresses cell migration and invasion by targeting paxillin in human colorectal cancer cells

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 2, 2015, Pages 1328-1340

  Qin, Jun ^a   Wang, Feiran ^a   Jiang, Haiyan ^a   Xu, Junfei ^a   Jiang, Yasu ^a   Wang, Zhiwei ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Colorectal cancer; Migration; miR 145; Paxillin; Proliferation

Indexed keywords

MICRORNA; MIRN145 MICRORNA, HUMAN; PAXILLIN;

CELL MOTION; CELL PROLIFERATION; COLORECTAL TUMOR; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; PAXILLIN;

EID: 84928136078     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Haggar FA and Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009; 22: 191-197.
2. Fearon ER and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
3. Shenouda SK and Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 2009; 28: 369-378.
4. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1: 882-891.
5. Du M, Liu S, Gu D, Wang Q, Zhu L, Kang M, Shi D, Chu H, Tong N, Chen J, Adams TS, Zhang Z and Wang M. Clinical potential role of circulating microRNAs in early diagnosis of colorectal cancer patients. Carcinogenesis 2014; 35: 2723-30.
6. de Krijger I, Mekenkamp LJ, Punt CJ and Nagtegaal ID. MicroRNAs in colorectal cancer metastasis. J Pathol 2011; 224: 438-447.
7. Feng Y, Zhu J, Ou C, Deng Z, Chen M, Huang W and Li L. MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1. Br J Cancer 2014; 110: 2300-2309.
8. Schepeler T, Holm A, Halvey P, Nordentoft I, Lamy P, Riising EM, Christensen LL, Thorsen K, Liebler DC, Helin K, Orntoft TF and Andersen CL. Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes. Oncogene 2012; 31: 2750-2760.
9. Turner CE. Paxillin and focal adhesion signalling. Nat Cell Biol 2000; 2: E231-236.
10. Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, Wheeler DL, Husain AN, Natarajan V, Vokes EE, Singleton PA and Salgia R. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biol Ther 2013; 14: 679-691.
11. Ketscher A, Jilg CA, Willmann D, Hummel B, Imhof A, Russeler V, Holz S, Metzger E, Muller JM and Schule R. LSD1 controls metastasis of androgen-independent prostate cancer cells through PXN and LPAR6. Oncogenesis 2014; 3: e120.
12. Chen DL, Wang ZQ, Ren C, Zeng ZL, Wang DS, Luo HY, Wang F, Qiu MZ, Bai L, Zhang DS, Wang FH, Li YH and Xu RH. Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer. J Transl Med 2013; 11: 277.
13. Wu DW, Chuang CY, Lin WL, Sung WW, Cheng YW and Lee H. Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by microRNA-218 targeting. Carcinogenesis 2014; 35: 1823-1829.
14. Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY, Qiu MZ, Ren C, Zhang DS, Wang ZQ, Wang FH, Li YH, Kang TB and Xu RH. Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis 2013; 34: 803-811.
15. Jun Q, Zhiwei W, Lilin M, Jing K and Qichao N. Effects of paxillin on HCT-8 human colorectal cancer cells. Hepatogastroenterology 2011; 58: 1951-1955.
16. Yin H, Zhang Q, Wang X, Li T, Wan Y, Liu Y and Zhu J. Role of paxillin in colorectal carcinoma and its relationship to clinicopathological features. Chin Med J (Engl) 2014; 127: 423-429.
17. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and Matsubara H. miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010; 127: 2804-2814.
18. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N and Nakagawa M. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 2010; 102: 883-891.
19. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M and Calin GA. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 2010; 17: 246-254.
20. Shao Y, Zhang SQ, Quan F, Zhang PF and Wu SL. MicroRNA-145 inhibits the proliferation, migration and invasion of the human TCA8113 oral cancer line. Oncol Lett 2013; 6: 1636-1640.
21. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N and Akao Y. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology 2009; 77: 12-21.
22. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A and Lund AH. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One 2010; 5: e8836.
23. Yang XW, Zhang LJ, Huang XH, Chen LZ, Su Q, Zeng WT, Li W and Wang Q. miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol Res 2014; 44: 551-559.
24. Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL, Chang YC, Chiou GY, Chou MY and Chiou SH. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 2013; 73: 3425-3440.
25. Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, Yacoubian AM, Behrman SW, Zafar N, Kumar D, Thompson PA, Jaggi M and Chauhan SC. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget 2014; 5: 7599-7609.
26. Akao Y, Nakagawa Y and Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 2006; 16: 845-850.
27. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L, Wiuf C, Sorensen FJ, Kruhoffer M, Laurberg S, Kauppinen S, Orntoft TF and Andersen CL. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008; 68: 6416-6424.
28. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T and Baserga R. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 2007; 282: 32582-32590.
29. Zhao Y, Zhang X, Guda K, Lawrence E, Sun Q, Watanabe T, Iwakura Y, Asano M, Wei L, Yang Z, Zheng W, Dawson D, Willis J, Markowitz SD, Satake M and Wang Z. Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci U S A 2010; 107: 2592-2597.
30. Turner CE. Paxillin interactions. J Cell Sci 2000; 113: 4139-4140.
31. Sattler M, Pisick E, Morrison PT and Salgia R. Role of the cytoskeletal protein paxillin in oncogenesis. Crit Rev Oncog 2000; 11: 63-76.
32. Huang C, Jacobson K and Schaller MD. A role for JNK-paxillin signaling in cell migration. Cell Cycle 2004; 3: 4-6.
33. Abou Zeid N, Valles AM and Boyer B. Serine phosphorylation regulates paxillin turnover during cell migration. Cell Commun Signal 2006; 4: 8.
34. Brown MC and Turner CE. Paxillin: adapting to change. Physiol Rev 2004; 84: 1315-1339.
35. German AE, Mammoto T, Jiang E, Ingber DE and Mammoto A. Paxillin controls endothelial cell migration and tumor angiogenesis by altering neuropilin 2 expression. J Cell Sci 2014; 127: 1672-1683.
36. Madan R, Smolkin MB, Cocker R, Fayyad R and Oktay MH. Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma. Hum Pathol 2006; 37: 9-15.
37. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, Loganathan S, Kanteti R, Reichman T, Nallasura V, Schwartz S, Faoro L, Wang YC, Girard L, Tretiakova MS, Ahmed S, Zumba O, Soulii L, Bindokas VP, Szeto LL, Gordon GJ, Bueno R, Sugarbaker D, Lingen MW, Sattler M, Krausz T, Vigneswaran W, Natarajan V, Minna J, Vokes EE, Ferguson MK, Husain AN and Salgia R. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res 2008; 68: 132-142.
38. Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, Hetland T and Kohn EC. Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome. Cancer 2012; 118: 1543-1553.
39. Sen A, De Castro I, Defranco DB, Deng FM, Melamed J, Kapur P, Raj GV, Rossi R and Hammes SR. Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation. J Clin Invest 2012; 122: 2469-2481.
40. Li HG, Xie DR, Shen XM, Li HH, Zeng H and Zeng YJ. Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol 2005; 11: 1445-1451.
41. Velasco-Velazquez MA, Salinas-Jazmin N, Mendoza-Patino N and Mandoki JJ. Reduced paxillin expression contributes to the antimetastatic effect of 4-hydroxycoumarin on B16-F10 melanoma cells. Cancer Cell Int 2008; 8: 8.
42. Li BZ, Lei W, Zhang CY, Zhou F, Li N, Shi SS, Feng XL, Chen ZL, Hang J, Qiu B, Wan JT, Shao K, Xing XZ, Tan XG, Wang Z, Xiong MH and He J. Increased expression of paxillin is found in human oesophageal squamous cell carcinoma: a tissue microarray study. J Int Med Res 2008; 36: 273-278.